Free Trial

Adaptive Biotechnologies Q4 2022 Earnings Report

Adaptive Biotechnologies logo
$6.18 -0.34 (-5.21%)
(As of 02:22 PM ET)

Adaptive Biotechnologies EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$0.43

Adaptive Biotechnologies Revenue Results

Actual Revenue
$55.20 million
Expected Revenue
$55.25 million
Beat/Miss
Missed by -$50.00 thousand
YoY Revenue Growth
+45.60%

Adaptive Biotechnologies Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

THIS is even better than AI (Ad)

The all-new Apollo Smart Algo is revolutionizing trading as we know it... Not only has this first-of-its-kind “smart algo” been averaging 2.8 wins per day since inception… On stocks that are on the verge of breaking out… But it tells you exactly when to buy in before the big move could happen!

Click Here to Experience the Future of Trading. 

Adaptive Biotechnologies Earnings Headlines

$20k in extra income?
My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k.
Adaptive Biotechnologies: Making Some Progress
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

View Adaptive Biotechnologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings